Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma
- PMID: 24497405
- PMCID: PMC4096173
- DOI: 10.1093/neuonc/nou006
Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma
Abstract
Background: The aim of this study was to prospectively examine the effects of hearing loss and posterior fossa syndrome (PFS), in addition to age at diagnosis and disease risk status, on change in intellectual and academic outcomes following diagnosis and treatment in a large sample of medulloblastoma patients.
Methods: Data from at least 2 cognitive and academic assessments were available from 165 patients (ages 3-21 years) treated with surgery, risk-adapted craniospinal irradiation, and 4 courses of chemotherapy with stem cell support. Patients underwent serial evaluation of cognitive and academic functioning from baseline up to 5 years post diagnosis.
Results: Serious hearing loss, PFS, younger age at diagnosis, and high-risk status were all significant risk factors for decline in intellectual and academic skills. Serious hearing loss and PFS independently predicted below-average estimated mean intellectual ability at 5 years post diagnosis. Patients with high-risk medulloblastoma and young age at diagnosis (<7 years) exhibited the largest drop in mean scores for intellectual and academic outcomes.
Conclusions: Despite a significant decline over time, intellectual and academic outcomes remained within the average range at 5 years post diagnosis for the majority of patients. Future studies should determine if scores remain within the average range at time points further out from treatment. Patients at heightened risk should be closely monitored and provided with recommendations for appropriate interventions.
Keywords: academic; cognitive; hearing; medulloblastoma; posterior fossa syndrome.
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
Similar articles
-
Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961.Pediatr Blood Cancer. 2013 Aug;60(8):1350-7. doi: 10.1002/pbc.24496. Epub 2013 Feb 26. Pediatr Blood Cancer. 2013. PMID: 23444345 Free PMC article. Clinical Trial.
-
Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study.J Clin Oncol. 2013 Oct 1;31(28):3494-500. doi: 10.1200/JCO.2012.47.4775. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980078 Free PMC article.
-
Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study.Neuro Oncol. 2017 Nov 29;19(12):1673-1682. doi: 10.1093/neuonc/nox135. Neuro Oncol. 2017. PMID: 29016818 Free PMC article.
-
Childhood medulloblastoma.Crit Rev Oncol Hematol. 2016 Sep;105:35-51. doi: 10.1016/j.critrevonc.2016.05.012. Epub 2016 Jun 15. Crit Rev Oncol Hematol. 2016. PMID: 27375228 Review.
-
Childhood medulloblastoma: progress and future challenges.Brain Dev. 1999 Mar;21(2):75-81. doi: 10.1016/s0387-7604(98)00085-0. Brain Dev. 1999. PMID: 10206522 Review.
Cited by
-
Anesthesia Exposure during Therapy Predicts Neurocognitive Outcomes in Survivors of Childhood Medulloblastoma.J Pediatr. 2020 Aug;223:141-147.e4. doi: 10.1016/j.jpeds.2020.04.039. Epub 2020 Jun 9. J Pediatr. 2020. PMID: 32532646 Free PMC article.
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma.Neuro Oncol. 2024 Oct 3;26(10):1912-1920. doi: 10.1093/neuonc/noae114. Neuro Oncol. 2024. PMID: 38916058 Free PMC article.
-
Assessment and Monitoring of Neurocognitive Function in Pediatric Cancer.J Clin Oncol. 2021 Jun 1;39(16):1696-1704. doi: 10.1200/JCO.20.02444. Epub 2021 Apr 22. J Clin Oncol. 2021. PMID: 33886364 Free PMC article. Review. No abstract available.
-
Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey.Pediatr Blood Cancer. 2020 Nov;67(11):e28647. doi: 10.1002/pbc.28647. Epub 2020 Sep 4. Pediatr Blood Cancer. 2020. PMID: 32886425 Free PMC article.
-
Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials.Cancer Med. 2018 Jul;7(7):2951-2959. doi: 10.1002/cam4.1563. Epub 2018 May 30. Cancer Med. 2018. PMID: 29846043 Free PMC article.
References
-
- Robinson KE, Kuttesch JF, Champion JE, et al. A quantitative meta-analysis of neurocognitive sequelae in survivors of pediatric brain tumors. Pediatr Blood Cancer. 2010;55(3):525–531. - PubMed
-
- Robinson KE, Fraley CE, Pearson MM, et al. Neurocognitive late effects of pediatric brain tumors of the posterior fossa: a quantitative review. J Int Neuropsychol Soc. 2013;19(1):44–53. - PubMed
-
- Gurney JG, Severson RK, Davis S, et al. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995;75(8):2186–2195. - PubMed
-
- Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813–820. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources